Merck Gives Away HIV Prevention Pill to 129 Countries

A major drug company is making sure an experimental HIV prevention pill reaches the people who need it most, even before the medicine gets approved.

Merck announced voluntary licensing deals with seven generic drug manufacturers to produce alimatravir, a once-a-month HIV prevention pill currently in final clinical trials. The agreements cover 129 low and middle-income countries and come with zero royalties, making it easier for generic companies to keep prices low.

Three of the manufacturers are based in Africa and four in India. They'll be allowed to sell the generic versions to both government health programs and private buyers, creating multiple pathways for people to access the medication.

What makes this move unusual is the timing. Alimatravir is still being tested in two late-stage clinical trials and hasn't received regulatory approval anywhere yet. Most pharmaceutical companies wait until a drug is approved before negotiating generic deals.

Merck's early action gives the generic manufacturers time to prepare for large-scale production and start the regulatory approval process in their countries. That means if the clinical trials succeed, the generic versions could become available much faster than usual.

The deals are royalty-free, which removes a major cost burden from the generic manufacturers. Without royalty payments to Merck, these companies can focus resources on production and distribution instead of licensing fees.

The Ripple Effect

The impact of these agreements could extend far beyond the 129 countries listed in the deals. When generic manufacturers can produce medication affordably, it often creates pricing pressure that benefits patients worldwide.

HIV prevention remains a critical global health priority. While existing prevention methods like daily pills and injections have made progress, a once-a-month oral medication could dramatically improve adherence rates. Many people struggle to take daily pills or access quarterly injections, but a monthly pill offers a middle ground.

By establishing these agreements now, Merck is essentially building the distribution infrastructure before the product exists. If alimatravir proves effective and safe in its ongoing trials, generic versions could reach patients within months of approval rather than years.

The pharmaceutical industry has faced intense criticism for keeping life-saving medications out of reach in poorer countries. These voluntary licensing deals represent a different approach, one where access planning happens alongside drug development rather than after.

Seven companies across two continents now have the green light to help end new HIV infections in the places where prevention tools are needed most.